Haifeng Shi | Infectious Diseases | Excellence in Research 

Dr. Haifeng Shi | Infectious Diseases | Excellence in Research 

Jiangsu University | China

Author Profile

Scopus

Dr. Shi Haifeng: Pioneer in Metal Toxicology and Cell Damage Detection 🔬

EARLY ACADEMIC PURSUITS 🎓

Dr. Shi Haifeng's academic journey began with a Bachelor’s degree in Biochemistry from Nanjing University in 1998. His passion for biochemistry led him to pursue a Ph.D. at the Hong Kong University of Science and Technology, where he studied under the mentorship of Professor Hong Xue, earning his doctorate in 2002. This foundation set the stage for his future groundbreaking research in the field of metal ion metabolism and toxicity.

PROFESSIONAL ENDEAVORS 🧑‍🔬

After obtaining his Ph.D., Dr. Shi continued his work at the Hong Kong University of Science and Technology as a Research Associate from 2002 to 2004, further honing his research skills. He then embarked on an international academic experience as a Visiting Scholar at the National Institutes of Health (NIH), specifically within the Liver Diseases Branch of the NIDDK, from 2004 to 2009. His time at the NIH allowed him to deepen his expertise in molecular toxicology and disease mechanisms.

CONTRIBUTIONS AND RESEARCH FOCUS ON INFECTIOUS DISEASES🧪

Dr. Shi’s research is focused on the metabolism and biological toxicity of metal ions such as iron, copper, and cadmium. His work is crucial in understanding how these metals impact biological systems, particularly in the context of heavy metal nephropathy. Additionally, his innovative work on the use of cell-free circulating cfDNA in blood as a biomarker for tissue cell damage has broad applications in medical diagnostics and environmental toxicology. His experimental models, which include yeast, silkworms, and mice, have helped to clarify the toxicological effects of metals at both molecular and systemic levels.

IMPACT AND INFLUENCE 🌍

Dr. Shi’s contributions to the scientific community are widely recognized. He has published over 70 research papers in prestigious international journals. One of his papers was recommended by Professor Alan Parrish from the University of Missouri-Columbia and listed by "Faculty Opinions" (formerly F1000Prime), a distinction reserved for papers with significant impact on their field. Another of his publications has been selected as an ESI Highly Cited Paper, placing him among the top 1% of researchers in his field.

ACADEMIC CITATIONS đź“š

Dr. Shi’s work is highly cited, and his recognition as an ESI Highly Cited Researcher underscores his influence on the global scientific community. His papers continue to guide researchers in the fields of toxicology, nephropathy, and medical diagnostics.

LEGACY AND FUTURE CONTRIBUTIONS 🏅

Dr. Shi Haifeng’s legacy lies in his groundbreaking work on the biological effects of heavy metals and his innovative use of cfDNA in disease detection. As a leader in his field, his future contributions are expected to expand the frontiers of biochemistry and toxicology, with significant implications for both environmental health and clinical medicine. His continued dedication to both research and education ensures that he will remain an influential figure in his field for years to come.

NOTABLE PUBLICATIONS đź“‘

"Cadmium promoted LPS-induced inflammation through TLR4/IκBα/NFκ-B signaling by increasing ROS-mediated incomplete autophagy" 

  • Authors: Guo, C. , Ruan, J. , Li, Z. , Gu, J. , Shi, H.
  • Journal: Ecotoxicology and Environmental Safety
  • Year: 2024

"From ferroptosis to cuproptosis, and calcicoptosis, to find more novel metals-mediated distinct form of regulated cell death" 

  • Authors: Gu, J. , Guo, C. , Ruan, J. , Gong, X. , Shi, H.
  • Journal: Apoptosis
  • Year: 2024

"Stimuli-triggered multilayer films in response to temperature and ionic strength changes for controlled favipiravir drug release" 

  • Authors: Xu, L. , He, L. , Li, Y. , Shi, H. , Zhu, C.
  • Journal: Biomedical Materials (Bristol)
  • Year: 2024

"Energy storage enabled by cross-linked multilayer films using block copolymer-modified nanocapsules and chitosan biopolymers" 

  • Authors: Xu, L. , Li, Y. , Cai, T. , Chu, Z. , Shen, X
  • Journal: Macromolecular Research
  • Year: 2024

"Analysis of the primary factors influencing donor derived cell-free DNA testing in kidney transplantation" 

  • Authors: Cao, C. , Yuan, L. , Wang, Y. , Shi, H. , Jiang, T.
  • Journal: Frontiers in Immunology
  • Year: 2024

Paritha Arumugam | Gene Therapy | Best Researcher Award

Dr. Paritha Arumugam | Gene Therapy | Best Researcher Award

Cincinnati Children's Hospital Medical Center | United States

AUTHOR PROFILE

Scopus

Orcid ID

EARLY ACADEMIC PURSUITS

Paritha Arumugam's academic journey began at the University of Madras, Bharathi Women's College, where she earned her B.Sc. in Biochemistry in 1991. She continued her education at the University of Madras, Guindy Campus, obtaining her M.Sc. in Biochemistry in 1993, M.Phil. in Biochemistry in 1994, and Ph.D. in Biochemistry in 1998 under the mentorship of Shyamala Devi, C.S. Her academic excellence was recognized with numerous awards, including the Gold Medal for securing the first rank in her M.Sc. program and various other prestigious prizes from the University of Madras.

PROFESSIONAL ENDEAVORS

Dr. Arumugam's professional career is marked by significant roles in both academic and research settings. She served as a Postdoctoral Research Fellow at the Children’s Hospital Los Angeles (CHLA) from 2004 to 2006, under the guidance of Dr. Punam Malik in the Division of Hematology-Oncology. She later earned an M.S. in Drug Development from the University of Cincinnati in 2011, where she was advised by Kevin L. Skare. Her academic appointments at the University of Cincinnati College of Medicine and Cincinnati Children’s Hospital Medical Center (CCHMC) have been pivotal. She progressed from Research Instructor in Pediatrics (2015-2019) to her current position as an Assistant Professor in Pediatrics at the Translational Pulmonary Science Center, Division of Pulmonary Biology, beginning in October 2019.

CONTRIBUTIONS AND RESEARCH FOCUS ON GENE THERAPY

Dr. Arumugam's research has significantly advanced the fields of biochemistry and molecular biology, with a particular focus on translational pulmonary science. Her work on developing a novel cell transplantation therapy, specifically Pulmonary Macrophage Transplantation, earned her a plenary talk at the NHLBI Celebration of 15 Years of Basic and Translational Progenitor Cell Research in 2023. Her research has garnered numerous awards, including the Excellence in Hemoglobinopathy Research Award from the National Institutes of Health and multiple abstract and travel awards from the American Society of Hematology.

IMPACT AND INFLUENCE

Dr. Arumugam's impact extends beyond her direct research contributions. Her role in advancing clinical practices is underscored by her licensing and certification in Good Clinical Practice for clinical trials involving drugs and devices. Her expertise in conducting investigator-initiated studies according to FDA regulations and GCP has positioned her as a leader in the field, capable of managing investigational agents and overseeing the ethical conduct of clinical trials.

ACADEMIC CITES

Dr. Arumugam's academic excellence has been recognized with several citations and awards throughout her career. Notably, she has been a recipient of the Cincinnati Children’s Innovation Excellence Award in 2023 and the NHLBI Celebration of 15 Years of Basic and Translational Progenitor Cell Research Poster Award. Her scholarly contributions are also highlighted by her selection as a Translational Sickle Scholar by the National Institutes of Health.

LEGACY AND FUTURE CONTRIBUTIONS

Dr. Arumugam's legacy is defined by her dedication to advancing medical science and improving clinical practices. Her pioneering research on pulmonary macrophage transplantation and her contributions to hemoglobinopathy research underscore her commitment to translational science. Looking forward, Dr. Arumugam aims to continue her impactful research, mentor the next generation of scientists, and contribute to significant advancements in pediatric pulmonary biology and therapeutic developments.

NOTABLE PUBLICATIONS

Neutrophil extracellular traps activate IL-8 and IL-1 expression in human bronchial epithelia 2020(52)

FOXM1 nuclear transcription factor translocates into mitochondria and inhibits oxidative phosphorylation 2020(28)

Thrombin-PAR1 signaling in pancreatic cancer promotes an immunosuppressive microenvironment 2021(27)

Role of GM-CSF in regulating metabolism and mitochondrial functions critical to macrophage proliferation 2022(26)

A murine model of hereditary pulmonary alveolar proteinosis caused by homozygous Csf2ra gene disruption 2022(8)